The DOI matches its Crossref record, with a small difference in title or year; 50 of the 52 references it cites were found in a registry or an index.
Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials
Open accessAbstract
Background—: Our objective was to estimate the comparative harms of individual statins using both placebo-controlled and active-comparator trials. Methods and Results—: We systematically reviewed randomized trials evaluating different statins in participants with and without cardiovascular disease. We performed random-effects pairwise and network meta-analyses to quantify the relative harms of individual statins. We included 55 two-armed placebo-controlled and 80 two- or multiarmed active-comparator trials including 246 955 individuals. According to pairwise meta-analyses, individual statins were not different than control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations because of adverse events. Statins as a class resulted in significantly higher odds of diabetes mellitus (odds ratio, 1.09; 95% confidence interval, 1.02–1.16) and transaminase elevations (odds ratio, 1.51; 95% confidence interval, 1.24–1.84) compared with control. When individual statins were compared in network meta-analyses, there were numerous statistically detectable differences, favoring simvastatin and pravastatin. According to dose-level comparisons, individual statins resulted in higher odds of discontinuations with higher doses of atorvastatin and rosuvastatin. Similarly, higher doses of atorvasatin, fluvastatin, lovastatin, and simvastatin were associated with higher odds of transaminase elevations. Simvastatin at its highest doses was associated with creatine kinase elevations (odds ratio, 4.14; 95% credible interval, 1.08–16.24). Meta-regression analyses adjusting for study-level age at baseline, low-density lipoprotein cholesterol level, and publication year did not explain heterogeneity. There was no detectable inconsistency in the network. Conclusions—: As a class, adverse events associated with statin therapy are not common. Statins are not associated with cancer risk but do result in a higher odds of diabetes mellitus. Among individual statins, simvastatin and pravastatin seem safer and more tolerable than other statins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In one study the baseline scores varied by almost 25% [24] and by 5-10% in two others [6,11].”
From Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“Other conditions, such as dementia [224], hepatic steatosis [225], venous thromboembolism [226], atrial fibrillation [227,228], and polycystic ovary syndrome [229] have also been studied, and no effect of statins on these conditions has been reliably demonstrated.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [224]
In the citing paper
“In meta-analyses of RCTs, no increased frequency in statin-treated groups has been shown. 213,214”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [214]
In the citing paper
“In meta-analyses of RCTs, no increased frequency in statin-treated groups has been shown.213,214”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [214]
In the citing paper
“A systematic review found that the incidence of drug-induced hepatotoxicity in patients taking statins is unknown, with very few cases occurring in large-scale RCTs.212,214”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [214]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,172
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Research works printed but not linked: 1
- Naci H Brugts J Fleurence R Ades AE. Comparative efficacy and safety of statins: a systematic review and mixed treatment comparison—final protocol. 2009; www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/HNaciProtocol.pdf. Accessed April 5 2013.
Cited by
Sorted by citations
Items 101–200 of 291
Lin, T., Lan, W.-H., Chiu, Y., Feng, C., Chiu, C., Kuo, C., & Lai, C. (2021) · Antioxidants · doi:10.3390/antiox10081293 · Cited by 24
Haines, D. D., Cowan, F. M., & Tósaki, Á. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116176 · Cited by 24
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 24
Zhao, J., Garcia, D., Gartung, A., & Lee, M.-J. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0504-y · Cited by 24
Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study
Olotu, B., Shepherd, M. D., Novak, S., Lawson, K. A., Wilson, J. P., Richards, K. M., & Rasu, R. S. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0176-1 · Cited by 25
Vevera, J., Fišar, Z., Nekovářová, T., Vrablı́k, M., Zlatohlávek, L., Hroudová, J., Singh, N., Raboch, J., & Valeš, K. (2016) · Physiological Research · doi:10.33549/physiolres.933264 · Cited by 24
Pedro‐Botet, J., Núñez-Cortés, J. M., Chillarón, J. J., Roux, J. A. F., & Rius, J. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1238068 · Cited by 24
Nasri, R., Abdelhedi, O., Jemil, I., Amor, I. B., Elfeki, A., Gargouri, J., Boualga, A., Karra‐Chaabouni, M., & Nasri, M. (2018) · RSC Advances · doi:10.1039/c7ra13102j · Cited by 24
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190326 · Cited by 23
Present status of statin therapy
Opie, L. H. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.002 · Cited by 22
Yang, Q., Zhong, Y., Gillespie, C., Merritt, R. K., Bowman, B. A., George, M. G., & Flanders, W. D. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-011684 · Cited by 22
Emerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
Venhuis, B. J., van Hunsel, F. P. A. M., van de Koppel, S., Keizers, P. H. J., Jeurissen, S. M. F., & de Kaste, D. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1929 · Cited by 21
Tratamiento de los factores de riesgo vascular en el paciente mayor de 80 años
Gómez‐Huelgas, R., Martínez‐Sellés, M., Formiga, F., Sánchez, J. J. A., Camafort, M., Galve, E., Gil, P., & Lobos, J. M. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.04.001 · Cited by 21
Pursnani, A. K., Mayrhofer, T., Ferencik, M., & Hoffmann, U. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.023 · Cited by 19
High exposure to statins decrease the risk of new-onset dementia
Chang, C.-F., Liou, Y., Lin, T., Ma, S., Hu, Y.-R., Chen, H., & Jong, G. (2019) · Medicine · doi:10.1097/md.0000000000016931 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 24
Singh, H., authorship., T. A. H. C. E. T. T. W. A. S. F., Sikarwar, P., authorship., T. A. H. C. E. T. T. W. A. S. F., Khurana, S., & Sharma, J. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.96 · Cited by 20
Bruckert, É., & Ferrières, J. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.01.011 · Cited by 19
Liao, K., Cheng, K.-C., Lin, C., & Lai, S. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12777 · Cited by 18
Soran, H., France, M. W., Adam, S., Iqbal, Z., Ho, J. H., & Durrington, P. N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.06.023 · Cited by 18
Fautrel, B., Balsa, A., van Riel, P. L. C. M., Casillas, M., Capron, J.-P., Cueille, C., & de la Torre, I. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1313209 · Cited by 19
Nogueira, A., Strunz, C. M. C., Takada, J. Y., & Mansur, A. D. P. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0379 · Cited by 18
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects
Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 19
Koskinas, K. C., Catapano, A. L., Baigent, C., Tokgözoğlu, L. S., & Mach, F. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa156 · Cited by 19
An Update on the Benefits and Risks of Rosuvastatin Therapy
Toth, P. P. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.03.2736 · Cited by 18
Risk of Statin-Induced Hypertransaminasemia
Villani, R., Navarese, E. P., Cavallone, F., Kubica, J., Bellanti, F., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2019) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.01.003 · Cited by 17
In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway
Haney, S. L., Varney, M. L., Chhonker, Y. S., Talmon, G. A., Smith, L. M., Murry, D. J., & Holstein, S. A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105528 · Cited by 17
Investigating raised creatine kinase
Kim, E. J., & Wierzbicki, A. S. (2021) · BMJ · doi:10.1136/bmj.n1486 · Cited by 19
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 64
Jeong, M. S., Park, S., Han, E. J., Park, S. Y., Kim, M. J., Jung, K., Cho, S.-H., Kim, S., Yoon, W., Ahn, G., et al. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104116 · Cited by 17
Pharmacogenomics of statin therapy
Hopewell, J. C., Reith, C. A., & Armitage, J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000125 · Cited by 17
Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
Shahreyar, M., Salem, S. A., Nayyar, M., George, L. K., Garg, N., & Koshy, S. K. G. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.04.170447 · Cited by 17
Management of Dyslipidemia for Cardiovascular Disease Risk Reduction
Tobert, J. A., & Newman, C. B. (2016) · Annals of Internal Medicine · doi:10.7326/l15-0523 · Cited by 17
Choi, H., Kang, S., Jeong, S.-W., Yoon, C., Youn, T., Song, W. H., Jeon, D. W., Lim, S. W., Lee, J.-H., Cho, S.-W., et al. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.3.277 · Cited by 17
A Review of Statin Use and Prostate Cancer
Pon, D., Abe, A. M., & Gupta, E. K. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0474-5 · Cited by 16
Sarma, A. A., Cannon, C. P., de Lemos, J. A., Rouleau, J. L., Lewis, E. F., Guo, J., Mega, J. L., Sabatine, M. S., & O’Donoghue, M. L. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000784 · Cited by 16
Takagi, H., & Umemoto, T. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.043 · Cited by 17
Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis
Mahjoubin‐Tehran, M., Teng, Y., Jalili, A., Aghaee‐Bakhtiari, S. H., Markin, A. M., & Sahebkar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094420 · Cited by 16
Sperry, M. M., Oskotsky, T., Marić, I., Kaushal, S., Takeda, T., Horváth, V., Powers, R. K., Rodas, M. J., Furlong, B. A., Soong, M., et al. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011050 · Cited by 15
Angelis, A. (2018) · MDM Policy & Practice · doi:10.1177/2381468318796218 · Cited by 15
Schulman, K. L., Lamerato, L. E., Dalal, M. R., Sung, J., Jhaveri, M., Koren, A., Mallya, U. G., & Foody, J. M. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.1858 · Cited by 14
Registered Randomized Trials Comparing Generic and Brand-Name Drugs: A Survey
Flacco, M. E., Manzoli, L., Boccia, S., Puggina, A., Rosso, A., Marzuillo, C., Scaioli, G., Gualano, M. R., Ricciardi, W., Villari, P., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.04.032 · Cited by 14
Nilsson, G. H., Samuelsson, E. C., Söderström, L., & Mooe, T. (2016) · BMC Family Practice · doi:10.1186/s12875-016-0505-0 · Cited by 14
Abdulhak, A. A. B., Vaughan‐Sarrazin, M., Kaboli, P. J., Horwitz, P. A., Mosher, H. J., Sigurðsson, G., Walker, N. E., Wallace, R. B., & Robinson, J. G. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007370 · Cited by 14
Yin, W., Al-Wabli, R. I., Attwa, M. W., Rahman, A. F. M. M., & Kadi, A. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-08804-x · Cited by 13
Hou, Q., Chen, Y., Zhang, Y., & Pang, C. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07405-0 · Cited by 13
Alqasrawi, M. N., Al-Mahayri, Z. N., Albawa’neh, A. S., Khasawneh, L. Q., Dabaghie, L., Altoum, S. M., Hamza, D., Misra, V., Ouda, H. Z., Aburuz, S., et al. (2025) · Human Genomics · doi:10.1186/s40246-025-00753-6 · Cited by 15
Statin therapy across the lifespan: evidence in major age groups
Stone, N. J., Turin, A., Spitz, J. A., Valle, C. W., & Kazmi, S. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1128825 · Cited by 13
Roy, D., Mahapatra, T., Manna, K., Kar, A., Rana, M. S., Roy, A., Bose, P. K., Banerjee, B., Paul, S., & Chakraborty, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233230 · Cited by 14
Association of statin use and increase in lipoprotein(a): a real-world database research
Feng, T., Li, Y., Xue, X., Yang, W. Y. L., Li, Q., Huang, Y., Zhu, T., Wang, J., Xu, L., Li, X., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01155-x · Cited by 12
The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease
Espinosa, E. V. P., Mato, E., Guzmán, D. M. S., & Khasawneh, F. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113179 · Cited by 14
Statins and new‐onset diabetes mellitus – a risk lacking in familial hypercholesterolaemia
Vuorio, A. F., Strandberg, T. E., Schneider, W. J., & Kovanen, P. T. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12405 · Cited by 12
Ma, H., Liang, W., Shan, M., Wang, X., Zhou, S., Chen, Y., Guo, T., Li, P., Hai-ya, Y., Liu, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15104 · Cited by 12
Li, H., Wang, C., Zhang, S., Sun, S., Li, R., Zou, M., & Cheng, G. (2016) · Drug Safety · doi:10.1007/s40264-016-0394-0 · Cited by 12
Budillon, A., Leone, A., Passaro, E., Silvestro, L., Foschini, F., Iannelli, F., Roca, M. S., Macchini, M., Bruzzese, F., García‐Bermejo, L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12936-w · Cited by 11
Statin withdrawal in people with dementia
McGuinness, B., Cardwell, C. R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012050.pub2 · Cited by 11
Anagnostis, P. G., Antza, C., Florentin, M., & Kotsis, V. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97845 · Cited by 10
Somers, T., Siddiqi, S., Maas, R. G. C., Sluijter, J. P. G., Buikema, J. W., van den Broek, P. H. H., Meuwissen, T. J., Morshuis, W. J., Rüssel, F. G. M., & Schirris, T. J. J. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-023-01025-x · Cited by 10
Múñoz, Ó., Peña, Á. A. G., Fernández, D., Higuera, A. M., Ruiz, Á. J., Aschner, P. J., Toro, J. M., Arteaga, J. M., Merchán, A., Vallejo, G. S., et al. (2015) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2015.02.001 · Cited by 10
Statin adverse effects: sorting out the evidence.
Mlodinow, S. G., Onysko, M. K., Vandiver, J. W., Hunter, M. L., & Mahvan, T. D. (2014) · PubMed · Cited by 10
A prospective study of hepatic safety of statins used in very elderly patients
Guo, M., Zhao, J., Zhai, Y., Zang, P., Lv, Q., & Shang, D. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1361-2 · Cited by 10
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Wan, S., Ding, Y., Ji, X., & Meng, R. (2021) · Aging and Disease · doi:10.14336/ad.2021.0412 · Cited by 9
Jiang, Z., Gong, R., Qiu, L., Wang, Q., Su, M., Liu, X.-J., Hu, M.-S., Lin, J., & Fang, D. (2014) · Clinical drug investigation · doi:10.1007/s40261-014-0215-0 · Cited by 8
Yebyo, H. G., Zappacosta, S., Aschmann, H. E., Haile, S. R., & Puhan, M. A. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01697-6 · Cited by 10
Treatment of Cholesterol in the Elderly: Statins and Beyond
LaRosa, J. C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0385-x · Cited by 10
Maghsoodi, N., & Wierzbicki, A. S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000282 · Cited by 10
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?
Bredefeld, C., Choi, P., Cullen, T., Nicolich-Henkin, S., & Waters, L. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01266-8 · Cited by 11
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 42
Wierzbicki, A. S., & Grant, P. S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-353 · Cited by 9
Utilizing Pharmacogenomic Data for a Safer Use of Statins among the Emirati Population
Alqasrawi, M. N., Al-Mahayri, Z. N., Alblooshi, H., AlSafar, H. S., & Ali, B. R. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611283841231227064343 · Cited by 9
Toth, P. P., Catapano, A. L., Farnier, M., Foody, J. M., Tomassini, J. E., Jensen, E. H., Polis, A. B., Hanson, M. E., Musliner, T. A., & Tershakovec, A. M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.071 · Cited by 9
Imaging subclinical coronary atherosclerosis to guide lipid management, are we there yet?
Piña, P., Lorenzatti, D., Paula, R., Daich, J., Schenone, A. L., Gongora, C. A., Garcia, M. J., Blaha, M. J., Budoff, M. J., Berman, D. S., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100451 · Cited by 10
A New American Amblyopone, With Notes on the Genus (Hymenoptera:Formicidae)
Brown, W. L. (1949) · Psyche A Journal of Entomology · doi:10.1155/1949/67378 · Cited by 9
Effect of statin on semen quality characteristics
Banihani, S. A. (2020) · Andrologia · doi:10.1111/and.13592 · Cited by 9
Amadid, H., Rønn, P. F., Dunbar, M. B., Knudsen, J. S., Carstensen, B., Persson, F., & Jørgensen, M. E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14478 · Cited by 8
How Low an LDL-C Should We Go With Statin Therapy?
Kostis, W. J. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0388-7 · Cited by 8
Xie, Y., Yao, K., Dong, Z., & Liu, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.029 · Cited by 8
Communication of Treatment Rankings Obtained From Network Meta-Analysis Using Data Visualization
Naci, H. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002874 · Cited by 8
Self-citationStatins and venous thromboembolism: do they represent a viable therapeutic agent?
Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., & Laukkanen, J. A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1357468 · Cited by 8
Pharmacokinetic Drug Interaction Between Rosuvastatin and Tanjin in Healthy Volunteers and Rats
Yang, J., Hasegawa, J., Endo, Y., Iitsuka, K., Yamamoto, M., & Matsuda, A. (2019) · Yonago acta medica · doi:10.33160/yam.2019.03.011 · Cited by 8
Yang, Z., Zhao, J., Li, J., Wang, J., & Wang, W. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112230 · Cited by 8
Tristantini, D., & Pradana, B. T. (2017) · AIP conference proceedings · doi:10.1063/1.4976778 · Cited by 7
Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study
Barkas, F., Adamidis, P. S., Koutsogianni, A.-D., Liamis, G. L., & Liberopoulos, E. N. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.111313 · Cited by 7
Flueckiger, P., Qureshi, W., Michos, E. D., Blaha, M. J., Burke, G. L., Sandfort, V., Herrington, D. M., & Yeboah, J. (2016) · Clinical Cardiology · doi:10.1002/clc.22642 · Cited by 7
Zouheira, D., Ngnokam, S. L. W., Kamani, S. L. P., Tchegnitegni, B. T., Jouda, J., Mba, J. R., Nchouwet, M. L., Nfor, N. G., Nyirimigabo, A. K., Kowa, T. K., et al. (2022) · BioMed Research International · doi:10.1155/2022/4145659 · Cited by 7
Wang, L. Y., Huang, Y., Perng, C., Huang, B., & Lin, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13009 · Cited by 7
To, M., Prakash, S., Poonnoose, S. I., & Bihari, S. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.01.184 · Cited by 7
Hepatotoxicity Induced by Fluvastatin: A Reversible Acute Cholestatic Liver Injury
Alanazi, N. S., Alenazi, T. S., & Alenzi, K. A. O. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.931418 · Cited by 7
Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation
Abrignani, M. G., Lucà, F., Abrignani, V., Nucara, M., Grosseto, D., Lestuzzi, C., Mistrangelo, M., Passaretti, B., Rao, C. M., & Parrini, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093083 · Cited by 6
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults
Bagherikholenjani, F., Shahidi, S., Vaseghi, G., Ashoorion, V., Sarrafzadegan, N., Siavash, M., Heidarpour, M., Shahidi, S., Sadeghi, M., Mohammadifard, N., et al. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_318_23 · Cited by 8
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 9
Do the immunosuppressive effects of statins increase M erkel cell carcinoma risk?
Mascitelli, L., & Goldstein, M. R. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12443 · Cited by 6
Lipid-Lowering Therapy after Acute Coronary Syndrome in Outpatient Practice—How to Achieve Goal
Rajtar-Salwa, R., Bobrowska, B., Batko, J., Bartuś, S., Dimitrow, P. P., & Krawczyk‐Ożóg, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206579 · Cited by 6
Corrao, G., Compagnoni, M. M., Cantarutti, A., Rea, F., Merlino, L. G., Catapano, A. L., & Mancia, G. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108197 · Cited by 6
Gelzleichter, T. R., Halpern, W., Erwin, R., Baruch, A., Leabman, M. K., Forrest, A. S., Satterwhite, C. M., Peng, K., Chilton, J. A., & Stevens, D. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu093 · Cited by 6
Statins and mortality: the untold story
Kostapanos, M. S., & Elisaf, M. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13202 · Cited by 5
Okere, A. N., & Serra, C. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1621 · Cited by 5
Okere, A. N., & Renier, C. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015603072 · Cited by 5
Metadata
- Authors
- Naci, H., Brugts, J., & Ades, T.
- Affiliations
- Erasmus MC (NL)
- From the LSE Health, London School of Economics and Political Science, London, United Kingdom (H.N.); Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands (J.B.); and .School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom (T.A.).
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2013-07
- Volume
- 6
- Issue
- 4
- Pages
- 390-399
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2160313369
- Cited by
- 292
- References
- 52
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 17 · 2023: 14 · 2022: 15 · 2021: 20 · 2020: 26 · 2019: 31 · 2018: 23 · 2017: 21 · 2016: 36 · 2015: 24 · 2014: 38 · 2013: 8
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Cardiovascular Quality and Outcomes (publishedVersion)
- PubMed (publishedVersion)
- London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
- London School of Economics and Political Science Research Online (London School of Economics and Political Science) (submittedVersion)
- Funders
- McMaster University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- statins, statin safety, tolerability, diabetes mellitus, transaminase elevation, creatine kinase elevation, myalgia, cancer risk, simvastatin, pravastatin, dose-response relationship, cardiovascular disease
- MeSH terms
- Cardiovascular Diseases, Dose-Response Relationship, Drug, Humans, Lipids, Risk Factors, Biomarkers, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
